Literature DB >> 12502825

Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons.

Robert E Lanford1, Bernadette Guerra, Helen Lee, Devron R Averett, Brad Pfeiffer, Deborah Chavez, Lena Notvall, Catherine Bigger.   

Abstract

The recently developed hepatitis C virus (HCV) subgenomic replicon system was utilized to evaluate the efficacy of several known antiviral agents. Cell lines that persistently maintained a genotype 1b replicon were selected. The replicon resident in each cell line had acquired adaptive mutations in the NS5A region that increased colony-forming efficiency, and some replicons had acquired NS3 mutations that alone did not enhance colony-forming efficiency but were synergistic with NS5A mutations. A replicon constructed from the infectious clone of the HCV-1 strain (genotype 1a) was not capable of inducing colony formation even after the introduction of adaptive mutations identified in the genotype 1b replicon. Alpha interferon (IFN-alpha), IFN-gamma, and ribavirin exhibited antiviral activity, while double-stranded RNA (dsRNA) and tumor necrosis factor alpha did not. Analysis of transcript levels for a series of genes stimulated by IFN (ISGs) or dsRNA following treatment with IFN-alpha, IFN-gamma, and dsRNA revealed that both IFNs increased ISG transcript levels, but that some aspect of the dsRNA response pathway was defective in Huh7 cells and replicon cell lines in comparison to primary chimpanzee and tamarin hepatocytes. The colony-forming efficiency of the replicon was reduced or eliminated following replication in the presence of ribavirin, implicating the induction of error-prone replication. The potential role of error-prone replication in the synergy observed between IFN-alpha and ribavirin in attaining sustained viral clearance is discussed. These studies reveal characteristics of Huh7 cells that may contribute to their unique capacity to support HCV RNA synthesis and demonstrate the utility of the replicon system for mechanistic studies on antiviral agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12502825      PMCID: PMC140845          DOI: 10.1128/jvi.77.2.1092-1104.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  68 in total

1.  Role for p53 in gene induction by double-stranded RNA.

Authors:  B T Hummer; X L Li; B A Hassel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 2.  A weak signal for strong responses: interferon-alpha/beta revisited.

Authors:  T Taniguchi; A Takaoka
Journal:  Nat Rev Mol Cell Biol       Date:  2001-05       Impact factor: 94.444

3.  Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

Authors:  H C Bodenheimer; K L Lindsay; G L Davis; J H Lewis; S N Thung; L B Seeff
Journal:  Hepatology       Date:  1997-08       Impact factor: 17.425

4.  Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays.

Authors:  S D Der; A Zhou; B R Williams; R H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

5.  Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes.

Authors:  R E Lanford; D Chavez; B Guerra; J Y Lau; Z Hong; K M Brasky; B Beames
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 6.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

7.  Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR.

Authors:  Nicole Pavio; Deborah R Taylor; Michael M C Lai
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

8.  NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling.

Authors:  S L Tan; H Nakao; Y He; S Vijaysri; P Neddermann; B L Jacobs; B J Mayer; M G Katze
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

9.  Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin.

Authors:  D Maag; C Castro; Z Hong; C E Cameron
Journal:  J Biol Chem       Date:  2001-10-15       Impact factor: 5.157

10.  Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase.

Authors:  Y L Yang; L F Reis; J Pavlovic; A Aguzzi; R Schäfer; A Kumar; B R Williams; M Aguet; C Weissmann
Journal:  EMBO J       Date:  1995-12-15       Impact factor: 11.598

View more
  69 in total

1.  Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication.

Authors:  Victor E Buckwold; Jiayi Wei; Michelle Wenzel-Mathers; Julie Russell
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

2.  Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

Authors:  Jean-Michel Pawlotsky
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

3.  A Genome-Wide CRISPR-Cas9 Screen Reveals the Requirement of Host Cell Sulfation for Schmallenberg Virus Infection.

Authors:  Thiprampai Thamamongood; Andrea Aebischer; Valentina Wagner; Max W Chang; Roland Elling; Christopher Benner; Adolfo García-Sastre; Georg Kochs; Martin Beer; Martin Schwemmle
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

4.  Serum Derived Transfer Factor Stimulates the Innate Immune System to Improve Survival Traits in High Risk Pathogen Scenarios.

Authors:  Bridget V Willeford; Trudy Shapiro-Dunlap; Kenneth O Willeford
Journal:  Drug Dev Res       Date:  2017-06-22       Impact factor: 4.360

Review 5.  The application and mechanism of action of ribavirin in therapy of hepatitis C.

Authors:  Emmanuel Thomas; Marc G Ghany; T Jake Liang
Journal:  Antivir Chem Chemother       Date:  2012-09-25

6.  Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain.

Authors:  Wenyu Lin; Sun Suk Kim; Elaine Yeung; Yoshitaka Kamegaya; Jason T Blackard; Kyung Ah Kim; Michael J Holtzman; Raymond T Chung
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 7.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 8.  Viral determinants of resistance to treatment in patients with hepatitis C.

Authors:  Anette Wohnsland; Wolf Peter Hofmann; Christoph Sarrazin
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

9.  Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons.

Authors:  Ju-Tao Guo; Qing Zhu; Christoph Seeger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells.

Authors:  MinKyung Yi; Stanley M Lemon
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.